Atyr Pharma Inc. (NASDAQ:LIFE)’s share price dropped 2.4% on Tuesday . The stock traded as low as $3.15 and last traded at $3.22, with a volume of 69,364 shares changing hands. The stock had previously closed at $3.30.

LIFE has been the topic of several analyst reports. Zacks Investment Research raised Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 target price on the stock in a research report on Tuesday, May 31st. BMO Capital Markets reaffirmed a “hold” rating on shares of Atyr Pharma in a research report on Thursday, May 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Atyr Pharma presently has a consensus rating of “Hold” and a consensus price target of $23.75.

The company’s 50-day moving average is $2.90 and its 200 day moving average is $3.80. The firm’s market cap is $75.32 million.

Atyr Pharma (NASDAQ:LIFE) last released its earnings results on Wednesday, May 11th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.70) by $0.02. On average, analysts expect that Atyr Pharma Inc. will post ($2.79) earnings per share for the current fiscal year.

In other news, insider Grove Matsuoka bought 12,412 shares of the firm’s stock in a transaction dated Wednesday, May 11th. The shares were acquired at an average price of $3.04 per share, for a total transaction of $37,732.48. Following the completion of the transaction, the insider now directly owns 2,412 shares in the company, valued at approximately $7,332.48. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

A hedge fund recently raised its stake in Atyr Pharma stock. RS Investment Management Co. LLC boosted its stake in shares of Atyr Pharma Inc. (NASDAQ:LIFE) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,206,249 shares of the company’s stock after buying an additional 124,000 shares during the period. RS Investment Management Co. LLC owned 5.10% of Atyr Pharma worth $11,857,000 as of its most recent SEC filing.

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.